Lineage Cell Therapeutics, Inc.

AMEX:LCTX

Biotechnology

Healthcare
$0.84 -2.80%

-$0.04 today

Market cap
$212.10M
Beta
1.51
P/E (TTM)
-4.6
EPS (TTM)
-$0.26
52W Low $0.85High $2.09

Volume 1.22M

Average 1.19M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$18.92M

FY 2025 · Annual

Investing Cash Flow

-$13.46M

FY 2025 · Annual

Financing Cash Flow

$26.95M

FY 2025 · Annual

-24.8% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(43.27M)(26.35M)(21.49M)(18.61M)(63.53M)
Depreciation & Amortization873K727K692K609K699K
Deferred Income Tax(6M)0(1.8M)0(5.28M)
Stock-Based Compensation3.52M4.29M4.64M5.08M4.75M
Change in Working Capital21.11M18.67M(10.8M)(8.77M)(4.11M)
Accounts Receivables(857K)50.31M(446K)106K(316K)
Inventory(72K)0000
Accounts Payables21.65M(18.7M)(2.3M)(1.68M)2.27M
Other Working Capital308K(12.94M)(8.06M)(7.19M)(6.07M)
Other Non-Cash Items202K3.73M195K(1.4M)48.55M
Operating Cash Flow(23.56M)1.06M(28.57M)(23.09M)(18.92M)
Capital Expenditures(354K)(413K)(674K)(565K)(522K)
Acquisitions (Net)10.09M45.75M000
Purchases of Investments6.02M(53.41M)(16.4M)(8.76M)(14.94M)
Sales of Investments(6.02M)7.67M63.53M7.02M2M
Other Investing Activities14K(45.75M)000
Investing Cash Flow9.75M(46.16M)46.45M(2.31M)(13.46M)
Debt Repayment(20K)(32K)(54K)(54K)(59K)
Common Stock Issued30.87M148K6.63M35.88M27.03M
Common Stock Repurchased(54K)(17K)(37K)(23K)0
Dividends Paid00000
Other Financing Activities6.14M1.53M(37K)58K(16K)
Financing Cash Flow36.93M1.63M6.42M35.86M26.95M
Effect of Forex Changes(20K)(873K)(250K)(95K)396K
Net Change in Cash23.09M(44.34M)24.06M10.36M(5.03M)
Free Cash Flow(23.92M)646K(29.24M)(23.66M)(19.44M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$63.5M
+ D&A$699.0K
+ Stock-Based Comp$4.8M
- Deferred Tax-$5.3M
- Working Capital-$4.1M
+ Other Non-Cash$48.6M
= Operating Cash Flow-$18.9M
- Capex-$522.0K
= Free Cash Flow-$19.4M

Analysis

FY2025 free cash flow is -$19.4M. FCF conversion is 30.6% of net income. Operating cash flow was -$18.9M, with capex of -$522.0K. The largest bridge item is Other Non-Cash at $48.6M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
10-QQuarterly reportNov 12, 2026
8-KCurrent reportNov 12, 2026
10-QQuarterly reportAug 6, 2026
8-KCurrent reportAug 6, 2026
SC 13GSC 13G filingJul 29, 2026

Does LCTX generate free cash flow?

Lineage Cell Therapeutics, Inc. (LCTX) generated -$19.44M of free cash flow in fiscal 2025.

How much operating cash flow does LCTX produce?

Operating cash flow was -$18.92M, before capital expenditures of $522,000.00.